Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it...
BioMed X Launches a New Call for Application in Autoimmune Disease Research
A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. BioMed X, an...
BioMed X and AbbVie Start New Research Project in the USA
BioMed X inaugurates its new institute in the USA with a research project on complex ex vivo models of tissue inflammation in collaboration with AbbVie....
New Documentary Focuses Lens on Relapsing Polychondritis Foundation, Racing, and Research
The Relapsing Polychondritis (RP) Foundation is pleased to announce the release of The Race of Our Lives, a documentary about Relapsing Polychondritis, an autoimmune disease....